logo

News2

25 Apr 2017
25 Apr 2017
25 Apr 2017

EpimAb Biotherapeutics Raises $25M in Series A Financing From International Consortium to Advance Pipeline of Novel Bispecific Antibodies

Shanghai, China, April 25, 2017 – EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, announced today the completion of a $25 million Series A financing round. The financing was led by Oriza Seed Capital and included investments from Decheng Capital, 3E Bioventures Capital and the Trend Investment Group. With the funding, Epimab will advance its proprietary bispecific platform technology and build a pipeline of therapeutic candidates in immuno-oncology and other areas with a high unmet medical need. […]

11 Oct 2016

Kymab and EpimAb Biotherapeutics Announce Multi-Target, Bispecific Antibody Cross-Licensing Agreement

Cambridge/UK and Shanghai/China, October 11, 2016 – Kymab, a leading human monoclonal antibody biopharmaceutical company, and EpimAb Biotherapeutics, an emerging biopharmaceutical company specializing in bispecific antibodies, today announced a cross-licensing and development agreement to develop bispecific therapeutic antibodies against multiple targets. The parties will focus their efforts on immuno-oncology and will combine EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig®) platform to generate multiple bispecific antibodies combined with antibodies sourced from Kymab’s proprietary Kymouse® platform. Kymab will have the development and commercialization rights […]

06 Jun 2016

EpimAb Biotherapeutics and Innovent Biologics Announce Multi-Target Bispecific Antibody Collaboration

Shanghai/Suzhou, June 6th, 2016 – EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, and Innovent Biologics, one of the leading biopharmaceutical companies in China, today announced a multiple target agreement for the development of bispecific antibodies. Under the terms of the agreement, Innovent will gain access to EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig®) platform to develop multiple bispecific antibodies for the Chinese market, including the right to out-license the developed programs outside of China. In return for commercialization […]

06 May 2016
06 Apr 2016